Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.

Justine GantzerGuillaume DavidsonBujamin VokshiNoëlle WeingertnerAntoine BougoüinMarco MoreiraVéronique LindnerGuillaume LacroixCéline MascauxMarie-Pierre ChenardFrançois BertucciIrwin DavidsonJean-Emmanuel KurtzCatherine Sautès-FridmanWolf H FridmanGabriel G Malouf

Published in: The oncologist (2022)

SMARCA4-UT mainly have an immune desert TME with limited efficacy to ICI. TME of SMARCA4-driven tumors varies according to the cell of origin questioning the interplay between BAF alterations, cell ontogeny and immunity.

Keyphrases

single cell
cell therapy
spinal cord
stem cells
bone marrow